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Abstract
Analyses were performed on brain MRI scans from individuals who were frequent cannabis users
(N = 10; 9 males, 1 female, mean age 21.1 ± 2.9, range: 18–27) in adolescence and similar age and
sex matched young adults who never used cannabis (N = 10; 9 males, 1 female, mean age of 23.0
± 4.4, range: 17–30). Cerebral atrophy and white matter integrity were determined using diffusion
tensor imaging (DTI) to quantify the apparent diffusion coefficient (ADC) and the fractional
anisotropy (FA). Whole brain volumes, lateral ventricular volumes, and gray matter volumes of the
amygdala-hippocampal complex, superior temporal gyrus, and entire temporal lobes (excluding the
amygdala-hippocampal complex) were also measured. While differences existed between groups,
no pattern consistent with evidence of cerebral atrophy or loss of white matter integrity was
detected. It is concluded that frequent cannabis use is unlikely to be neurotoxic to the normal
developing adolescent brain.
Introduction
Cannabis abuse is considered a major public health prob-
lem worldwide [1] and moreover, cannabis is the most
frequent drug of abuse among adolescents [2]. Despite
being illegal in many countries it is easily obtainable and
even homegrown. Most individuals who frequently use it
report a mild euphoric feeling and sense of wellbeing, a
reason for its continual popularity. However in some indi-
viduals, frequent use has adverse consequences and can
even lead to psychotic symptoms (reviewed in [3]). The
adolescent brain may be particularly sensitive to any
effects it may have because of the continued growth and
differentiation of higher brain cortical centers throughout
these specific years of life [4].
In the early 1970's a controversial report was published in
the Lancet concluding that cannabis caused cerebral atro-
phy as evidence in a pneumoencephalography study of a
small group of male users [5]. This was followed by sev-
eral CT studies in the 1970's and 80's that refuted these
findings [6-9]. More recently, two MRI studies [10,11]
reported no difference in gray or white matter vollumes,
CSF, or hippocampus volumes in heavy cannabis users
compared with non-users. However, specific measures of
white matter change were not examined and the subjects
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studied were not necessarily adolescent cannabis users.
Since cannabis use changes the density of cannabinoid -1
receptors in the brain [12], it is possible that this density
alteration could be associated with volume loss as detect-
able by MRI in cannabinoid receptor rich brain regions,
such as temporal cortex. In one study, Nerve Growth Fac-
tor (NGF), which is known to be released after neuronal
damage, was found to be increased in serum subsequent
to cannabis use and could be evidence of neurotoxicity
[13]. While there is no convincing evidence that cannabis
is neurotoxic, the establishment of new cortical connec-
tions and growth of axons that normally occur during
adolescence could be disrupted by frequent cannabis use.
Diffusion tensor imaging (DTI) is particularly useful to
test this hypothesis.
DTI is an MRI technique that measures the Brownian
motion or free diffusion of water [14]. Images obtained
using DTI are used to estimate a diffusion tensor, D, for
each voxel, which models the water diffusion. The diffu-
sion tensor can be further processed to compute the frac-
tional anisotropy (FA), a normalized scalar measure of the
degree of diffusion anisotropy within a voxel. FA reflects
the degree of fiber organization, fiber directional coher-
ence, or fiber integrity. White matter abnormalities with
axonal disorganization might therefore be expected to
have decreased FA. DTI may also be used to assess regional
volume deficits using ADC-based morphometry (ABM;
[15]), although this association has never been directly
validated. Voxelwise ADC is computed as the trace of the
diffusion tensor D and compared between groups. ABM
relies on the assumption that reductions in brain volume
are accompanied by commensurate increases in the local
volume of CSF. Because the ADC of CSF is greater than
that of brain parenchyma, one would expect an increase in
ADC in voxelwise group analyses in regions with volume
deficits.
Thus, the current report uses DTI to address whether can-
nabis affects normal brain structures and their white mat-
ter integrity during adolescence.
Methods
Young adults (between the ages of 17 to 30) were
recruited for this study either by use of a research normal
volunteer pool at The Nathan S Kline Institute for Psychi-
atric Research (NKI) or by direct advertisement. The NKI
volunteer pool was established in the research outpatient
department to develop a cohort of community individu-
als who are available for participation in multiple human
research studies. They are ascertained through advertise-
ment in the local communities surrounding the institute.
Others were recruited directly by advertisements for nor-
mal participants for research studies. Individuals were not
recruited based on whether they had a history of cannabis
use or not and advertisements did not mention cannabis.
Cannabis users were consecutively admitted into the
study if the cannabis use began prior to the age of 18 and
consisted of use more than 21 times in any single year (N
= 10; 9 males, 1 female, mean age 21.1 ± 2.9, range 18–
27). This cut-off was chosen based on the cut-off already
established by the structured interview format used
(DIGS, [16]). All 10 positive adolescent users were not
current frequent users; but their periods of use ranged
from daily for one or more years to 2–3 times per week for
1 or more years during adolescence. Of these, 3 also
admitted to having used other illicit drugs as well in the
past (not currently) as well as frequent alcohol use in the
past, two of them at the time of this study. No others were
frequent alcohol users. Control subjects were admitted
into the study if they had no illegal substance use, no fre-
quent alcohol use in the past or currently and were not
taking any medication for long periods. They were
matched one to one to each cannabis user for sex first and
then as close as possible to age and to social class (years of
education and occupational status) of parents from a
group of consecutively obtained controls who had MRI
scans performed. The 10 matched non-user controls were
9 males and 1 female, mean age of 23.0 ± 4.4 (range: 17–
30). The 10 cannabis users were the first 10 controls
obtained who admitted to cannabis use according to the
above criteria. No volunteer who had evidence of a psy-
chosis by DIGS interview was admitted into the study.
Individuals who had a family history of schizophrenia in
a first or second degree relative were eliminated from this
analysis because studies of individuals at genetic high risk
for schizophrenia within our research program show
brain differences compared with controls (unpublished
data). All individuals signed written informed consent for
participation in this research. The MRI scan protocol was
approved by the Center for Advanced Brain Imaging at
NKI and the Institutional Review Board. All subjects
signed written informed consent for participation in an
MRI study.
MRI scans were performed on a 1.5 T Siemens Vision sys-
tem (Erlangen, Germany). Image sequences acquired
included: a 3D magnetization-prepared rapid gradient
echo (MPRAGE) image (TR/TE = 11.6/4.9 ms, flip angle
8°, 256 × 256 × 172 matrix size, 1.20 × 1.20 × 1.20 mm3
voxel size), a T2-weighted spin-echo image (TR/TE =
5000/90 ms, 24 slices, 5 mm slice thickness, no gap, 256
× 256 matrix size, 0.88 × 0.88 mm2 pixel size), diffusion
weighted images (TR/TE = 6000/100 ms, b-value = 1000
s/mm2, 8 non-collinear gradient orientations, 7 averages,
19 slices, 5 mm slice thickness, no gap, 128 × 128 matrix
size, 2.5 × 2.5 mm2 pixel size), and one image without dif-
fusion sensitizing gradients (b = 0).Harm Reduction Journal 2006, 3:17 http://www.harmreductionjournal.com/content/3/1/17
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The processing steps for voxelwise analyses of the FA and
ADC maps were exactly the same. The 8 DTI volumes with
(b = 1000 s/mm2) and the one volume without diffusion
gradients (b = 0) were used to estimate a second order
symmetric diffusion tensor D  at each voxel [14], from
which the FA and ADC values were computed. The com-
puted FA and ADC maps were spatially normalized to a
standard space to facilitate voxelwise statistical analysis.
Details of the registration process are given elsewhere
[17].
To assess the between group differences in the FA or ADC
maps of the subjects with and without cannabis use, two-
tailed voxel-wise independent samples student's t-tests
were used. The obtained t-map was then threshold at P <
0.01 to find voxels where the FA or ADC values signifi-
cantly differed between the groups. To reduce the false-
positive rate, clusters of size 200 mm3 or greater in the
thresholded image were retained (see [17]).
Volumetric measurements were obtained of whole brain,
temporal lobe, the superior temporal gyrus, hippocampus
and amygdala as a complex and cerebral ventricles These
structures were chosen because they most often are related
to psychotic experiences and memory. Since cannabis can
occasionally lead to psychotic experiences and transient
cognitive problems, focusing on these brain regions
seemed warranted. For all volumetric measurements T1-
weighted MPRAGE images were used. The T1 images were
resliced into 2 image sets: One set to be used in automated
tissue segmentation for white matter FA tissue masking;
these co-registered images were resliced using the pixel
dimensions of the FSE images (2.5 mm3 × 40 slices). The
segmented FA masks were used for global white matter FA
determinations; The second image set was used for the
evaluation of gray matter volumetric measures and were
resliced using the original pixel sizes (1.2 mm3 × 172
slices). The slice editing software 3D Slicer [18] was used
for localization of anatomical landmarks, manual seg-
mentation of anatomical regions of interest (ROIs), and
the creation of regional ROIs from grey/white segmented
images (measurement reliability ranged from an ICC of
0.99 for ventricles and hemispheres, .93 for left and .97
for right temporal lobes, .91 left and .93 for right superior
temporal gyrus and .85 for left and .89 right amygdala-
hippocampal complex). This program permits optimized
visualization of anatomical MRI data and allows for man-
ual segmentation in all image planes as well as landmark
identification in multiple planes simultaneously. 3D
Slicer is freely available, open-source software available
for a variety of operating systems including Linux and
Windows. Atlases [19,20], depicting three-dimensional
sectional anatomy and describing variations in cerebral
sulcal anatomy, were also used as aids. All manual delin-
eations were performed separately for each hemisphere
on coronal slices containing the structure of interest. Sag-
ittal and axial views were used for anatomical reference.
Whole brain measurements included both the cerebellum
and lateral ventricles, and were solely used to control for
brain size in testing hypotheses about specific structures.
These data were analyzed for group differences using an
ANCOVA controlling for whole brain size and age. Ven-
tricular size was considered an indicator of overall atro-
phy.
Anatomical locations for any statistically significant dif-
ferences were determined using AFNI [21]. AFNI provides
Talairach coordinates for a spatially registered image.
These images are then checked against standard Talairach
atlases for corresponding anatomical structures [19].
Results
Volumetric measurements
Table 1 shows no significant change in any measured
brain structures in the cannabis users compared with con-
trols.
Voxelwise analyses
There were two regions (p < 0.01, cluster size > 200 mm3)
where the ADC was reduced in cannabis users relative to
non-users. These are shown in Fig. 1, parts (a) and (b).
There were no regions where the ADC was significantly
increased. There were six regions (p < 0.01, cluster size >
200 mm3) where the FA was increased in cannabis users
relative to non-users. These regions are shown in Fig. 1,
parts (c)-(h). The FA was not reduced in any regions in
cannabis users compared with non-users. Because these
results did not show any increases in ADC or reductions
in FA in cannabis users, we relaxed the significance level
to p < 0.05 without a change in the direction of the results.
Thus only the p < 0.01 maps are shown.
Discussion
Adolescence is a time of particular vulnerability for brain
maturation. During this period many individuals experi-
ment with illicit substance use and sometimes quite fre-
quently. Some adolescents who abuse cannabis
subsequently develop chronic serious psychiatric symp-
toms, such as schizophrenia (e.g. [22]) and also cognitive
deficits [23-25]. However, it has never been shown con-
sistently that cannabis has direct effects on brain develop-
ment and there are no known reports using more
advanced imaging technology such as DTI to examine
white matter integrity. Thus the current study was an ini-
tial evaluation to determine whether any indication of
cortical atrophy or white matter abnormalities could be
detected applying these current MRI methods.
Although differences were observed between subjects who
used cannabis during adolescence and those who did not,Harm Reduction Journal 2006, 3:17 http://www.harmreductionjournal.com/content/3/1/17
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no finding indicated pathological change. Regions of
higher ADC, putative evidence of atrophy, were not
present, although regions of significantly lower ADC
were. While low FA would be indicative of less white mat-
ter integrity, particularly with respect to fiber direction, all
FA differences in this study were higher values in cannabis
users than non-users.
However, one limitation of the current study is its cross-
sectional evaluation of subjects reporting on their own
former adolescent cannabis use, rather than a longitudi-
nal design following adolescents into adulthood to
observe how the brain changes over time or alternatively
a cross-sectional study of current cannabis-using adoles-
cents. Pathological effects from prior frequent use may be
less detectable in adulthood after time has passed and
other changes have taken place to compensate for possi-
ble earlier effects of cannabis.
In addition, although we suggest here that the ADC indi-
cates the amount of CSF in extracellular tissue and ven-
tricular space, we have not yet validated this assumption
by direct comparisons and thus this view, while logical,
remains speculative at present.
Thus, these data lead to the likely conclusion that canna-
bis use, in at least moderate amounts, during adolescence
does not appear to be neurotoxic, although we cannot
exclude any adverse effects of heavier amounts than that
used by the current subjects. These data are preliminary
and need replication with larger numbers of subjects,
although they do have implications for refuting the
hypothesis that cannabis alone can cause a psychiatric dis-
turbance such as schizophrenia by directly producing
brain pathology.
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This figure illustrates significant differences in cannabis users relative to non-users in both ADC and FA Figure 1
This figure illustrates significant differences in cannabis users relative to non-users in both ADC and FA. Coronal, sagittal and 
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middle frontal gyrus (a): Talairach coordinates -41 [L],3 [A],36 [S], and posterior to the right posterior cingulate (b): 2 [R],-54 
[P],4 [S] (shown in orange superimposed on the average registered MPRAGE images from all 20 subjects), and that the frac-
tional anisotropy (FA) was significantly higher (shown in blue) in cannabis users in the left anterior cingulate (c): -16 [L],32 
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